Monoclonal antibodies: Will they become an integral part of the evaluation and treatment of prostate cancer-focus on prostate-specific membrane antigen?

Current Opinion in Urology

Volumn 9, Issue 5, 1999, Pages 391-395

  Chang, Sam S ^a   Bander, Neil H ^b   Heston, Warren D W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; VASCULOTROPIN;

HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SHORT SURVEY; TUMOR VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; HUMANS; MALE; ORGAN SPECIFICITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0033400497     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-199909000-00004     Document Type: Short Survey

References (39)

1. 1 Meyers JF, Denardo SJ, Macey D, White RD, Unger M. Development of monoclonal antibody imaging of metastatic prostatic carcinoma. The Prostate 1989; 14:209-220.
2. 111indium-labeled monoclonal antibody PAY 276. J Urol 1987; 137:439-443.
3. 3 Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 1987; 7:927-936.
4. 4 Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996; 2:1445-1451.
5. 5 Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther 1998; 286:1020-1025.
6. 6 Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82:2256-2261. This group examined 184 cases and convincingly showed that PSMA expression increases in cancer and represents an attractive antigen target.
7. 7 Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54:1807-1811.
8. 8 Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 1990; 50:6423-6429.
9. 9 Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997; 57:2321-2324.
10. 10 Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48:326-334.
11. 11 Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57:3629-3634.
12. 12 Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3:81-85.
13. 13 Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-PSMA antibodies confirm prostate-specific membrane antigen (PSMA) expression in tumor-associated neovasculature. Cancer Res 1999; 59:3192-3196.
14. 14 Troyer JK, Beckett ML, Wright GL Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997; 30:232-242.
15. 15 Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM protein in the LNCaP prostatic carcinoma cell line. Cancer Res 1998; 58:4787-4789.
16. 16 Murphy GP, Greene TG, Tino WT, Boynton AL, Holmes EH. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urol 1998; 160:2396-2401.
17. 17 Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 1998; 37:261-269. This study was the first to establish a correlation between increased PSA/Gleason score and the likelihood of a positive ProstaScint scan.
18. 18 Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med 1998; 23:672-677.
19. 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994; 152:1490-1495.
20. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 1998; 159:2041-2046; discussion 2046-2047.
21. 21 Kahn D, Williams RD, Haseman MK, Reed NL, Miller SJ, Gerstbrein J. Radioimmunoscintigraphy with ln-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 1998; 16:284-289. A multi-institutional trial examining the sensitivity and specificity of the ProstaScint scan.
22. 111indium-labeled monoclonal antibody CYT-356. J Urol 1994; 152:1952-1955.
23. 23 Texter JH Jr, Neal CE. The role of monoclonal antibody in the management of prostate adenocarcinoma. J Urol 1998; 160:2393-2395.
24. 111In-Capromab pendetide immunoscintigraphy to predict lymph node involvement in high-risk prostate cancer patients. Cancer 1999; 85:1586-1592. In a large cohort of patients (198), ProstaScint was found to be better able to predict positive lymph node involvement than prognostic tables for T2-T4 tumors. The combination of algorithms and scan were found to have a positive predictive value of 72% in this cohort of patients.
25. 25 Manyak MJ, Javitt MC. The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. Semin Urol Oncol 1998; 16:145-152.
26. 26 Michaels EK, Blend M, Quintana JC. Indium-capromab pendetide unexpectedly localizes to renal cell carcinoma. J Urol 1999; 161:597-598.
27. 27 Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, et al. Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate 1998; 37:140-148.
28. 28 Murphy GP, Elgamal A.A., Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998; 83:2259-2269. An excellent review of PSMA distribution and current targeting applications using different anti-PSMA antibodies.
29. 29 O'Keefe DS, Su SL, Bacich DJ. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1443:113-127.
30. 30 Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998; 160:459-465. A total of 149 prostatectomy specimens were examined with the monoclonal antibody CD34 to determine microvessel density. They found that microvessel density did increase with increasing Gleason score, and although longer follow-up and study are necessary, CD34 may be another prognostic marker.
31. 31 Mydlo JH, Kral JG, Volpe M, Axotis C, Macchia RJ, Pertschuk LP. An analysis of microvessel density, androgen receptor, p53 and HER2-neu expression and Gleason score in prostate cancer. Eur Urol 1998; 34:426-432.
32. 32 Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 1996; 2:1289-1297.
33. 33 Heston WD. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology 1997; 49 (3A Suppl.):104-112.
34. 34 Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58:4055-4060.
35. 35 Gong MC, Latouche JB, Krause A, Heston WDW, Bander NH, Sadelain M. Prostate cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically and efficiently lyse prostate cancer cells. Neoplasia 1999;123-127.
36. 36 O'Donnell RT, De Nardo SJ, Shi XB, Mirick GR. DeNardo GI, Kroger LA, Meyers FJ. L6 monoclonal antibody binds prostate cancer. The Prostate 1998; 37:91-97.
37. 37 Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999; 161:960-963.
38. 38 Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998; 4:295-302.
39. 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 1998; 4:643-651.